Karen Brunke - Jaguar Animal Executive Development
| JAGX Stock | USD 0.94 0.03 3.09% |
Executive
Karen Brunke is Executive Development of Jaguar Animal Health
| Age | 72 |
| Address | 200 Pine Street, San Francisco, CA, United States, 94104 |
| Phone | 415 371 8300 |
| Web | https://jaguar.health |
Jaguar Animal Management Efficiency
The company has return on total asset (ROA) of (0.3453) % which means that it has lost $0.3453 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.9094) %, meaning that it created substantial loss on money invested by shareholders. Jaguar Animal's management efficiency ratios could be used to measure how well Jaguar Animal manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.41 in 2024. Return On Capital Employed is likely to rise to -0.89 in 2024. At this time, Jaguar Animal's Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 29.4 M in 2024, whereas Total Assets are likely to drop slightly above 31.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Verender Badial | Zura Bio Limited | 52 | |
| Rajesh Kapoor | Vaxart Inc | N/A | |
| CMA CPA | Ocugen Inc | N/A | |
| Gael Hedou | Sonnet Biotherapeutics Holdings | 52 | |
| MPH MD | Tonix Pharmaceuticals Holding | N/A | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Sean Tucker | Vaxart Inc | 56 | |
| Darryl Rideout | Tonix Pharmaceuticals Holding | N/A | |
| Marc JD | Ibio Inc | N/A | |
| Linda Mahoney | Phio Pharmaceuticals Corp | N/A | |
| John Sharkey | GeoVax Labs | 68 | |
| Sina Bavari | Tonix Pharmaceuticals Holding | N/A | |
| Kiran MBBS | Zura Bio Limited | 51 | |
| Dr MBA | Tonix Pharmaceuticals Holding | 66 | |
| Gregory MD | Tonix Pharmaceuticals Holding | 58 | |
| Edward Berg | Vaxart Inc | 60 | |
| John JD | Ocugen Inc | N/A | |
| David Brady | Zura Bio Limited | N/A | |
| MD FACC | ZyVersa Therapeutics | 74 | |
| Felipe Duran | Ibio Inc | 45 | |
| Kristen Craft | Ocugen Inc | N/A | |
Management Performance
| Return On Equity | -2.91 | ||||
| Return On Asset | -0.35 |
Jaguar Animal Health Leadership Team
Elected by the shareholders, the Jaguar Animal's board of directors comprises two types of representatives: Jaguar Animal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jaguar. The board's role is to monitor Jaguar Animal's management team and ensure that shareholders' interests are well served. Jaguar Animal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jaguar Animal's outside directors are responsible for providing unbiased perspectives on the board's policies.
| DVM MS, VP Studies | ||
| Ian MBA, Chief Officer | ||
| Pravin Chaturvedi, Chief Board | ||
| Peter Hodge, Business Relations | ||
| Carol MBA, Chief Officer | ||
| Karen Brunke, Executive Development | ||
| Steven King, Executive VP of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary | ||
| Catherine Collis, Senior Strategy | ||
| Lisa Conte, CEO and President and Director | ||
| CPA JD, Chief Staff | ||
| Massimo MBA, President International | ||
| David Sesin, Chief Officer | ||
| Carol Lizak, Chief Officer |
Jaguar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jaguar Animal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.91 | ||||
| Return On Asset | -0.35 | ||||
| Operating Margin | (2.65) % | ||||
| Current Valuation | 32.44 M | ||||
| Shares Outstanding | 11.8 M | ||||
| Shares Owned By Insiders | 12.02 % | ||||
| Shares Owned By Institutions | 1.95 % | ||||
| Number Of Shares Shorted | 515.26 K | ||||
| Price To Earning | (0.96) X | ||||
| Price To Book | 0.84 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Jaguar Stock Analysis
When running Jaguar Animal's price analysis, check to measure Jaguar Animal's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jaguar Animal is operating at the current time. Most of Jaguar Animal's value examination focuses on studying past and present price action to predict the probability of Jaguar Animal's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jaguar Animal's price. Additionally, you may evaluate how the addition of Jaguar Animal to your portfolios can decrease your overall portfolio volatility.